Novel Diagnostic and Prognostic Predictors in Fabry Cardiomyopathy: Proof of Concept in a Rare Disease
- Sponsor
- Núcleo de Apoio à Investigação Clínica - FMUP
- Study ID
- NCT07351136
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- PET scan of 68Ga-FAPI — PROCEDURETo assess myocardial fibroblast activation, all enrolled patients will undergo positron emission tomography/computed tomography (PET/CT) imaging using the radiotracer \[68Ga\]Ga-FAPI. This tracer binds selectively to the fibroblast activation protein (FAP), expressed predominantly in activated cardiac fibroblasts involved in pathological myocardial remodelling.
Study Details
In this work, we address the understanding of the signaling pathways involved in cardiac remodeling in human SCD through molecular imaging analysis with a fibrosis marker. Furthermore, we emphasize characterizing the cardiac remodeling process by analyzing proteomic data from SCD myocardial biopsies and by analyzing the profile of microRNAs associated with hypertrophic cardiomyopathy and their diagnostic and prognostic value.
Key Dates
- Start date
- Jan 1, 2026
- Status verified
- Oct 2025
- Primary completion
- Jan 31, 2026
- Completion
- Mar 31, 2026
Study Design
- Enrollment
- 20 participants (estimated)
Arms
- Arm: adults with Fabry disease
Primary Outcome Measure
Identify and validate novel molecular biomarkers and pathophysiological mechanisms of FD cardiomyopathy, focusing on myocardial fibrosis, inflammation, and cardiac remodelling [ Time Frame: All enrolled patients will undergo PET/CT imaging using the radiotracer [68Ga]Ga-FAPI. This procedure will be done from October 2025 to January 2026. The data analysis will be done from January 2026 to April 2026 ]
Related Studies
- Fabry Disease Registry & Pregnancy Sub-registryRecruiting · Genzyme, a Sanofi Company · Birmingham, Alabama
- Natural History and Structural Functional Relationships in Fabry Renal Disease Treatment Outcomes(Changes)in Fabry Renal Disease StudyRecruiting · University of Minnesota · Minneapolis, Minnesota
- A Global Prospective Observational Study of Women With Fabry Disease and Their Infants During Pregnancy and BreastfeedingRecruiting · Amicus Therapeutics · Philadelphia, Pennsylvania
- Long-Term Follow-up of Subjects Who Were Treated With ST-920Enrolling By Invitation · Sangamo Therapeutics · Irvine, California